Novel antimicrobial peptide—modified azithromycin-loaded liposomes against methicillin-resistant Staphylococcus aureus

International Journal of Nanomedicine

Volumn 11, Issue , 2016, Pages 6781-6794

  Liu, Xiaowei ^a   Li, Zhan ^a   Wang, Xiaodong ^a,b   Chen, Yujuan ^a,b   Wu, Fengbo ^a,b   Men, Ke ^a   Xu, Ting ^a,b   Luo, Yan ^a   Yang, Li ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Antimicrobial resistance; Azithromycin; DP7 C; Immune regulation; MRSA infections

Indexed keywords

ANTIBACTERIAL PEPTIDE DP7 C; ANTIBACTERIAL PEPTIDE DP7 C MODIFIED AZITHROMYCIN; AZITHROMYCIN; CHEMOKINE; LIPOSOME; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CYTOKINE; LIPID BILAYER; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ENCAPSULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LIPID BILAYER; MAMMAL CELL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOUSE; NONHUMAN; NORMAL HUMAN; SUSTAINED DRUG RELEASE; UPREGULATION; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; HEK293 CELL LINE; METABOLISM; MICROBIAL SENSITIVITY TEST; MONONUCLEAR CELL; PARTICLE SIZE; PENICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; AZITHROMYCIN; CYTOKINES; FEMALE; HEK293 CELLS; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPID BILAYERS; LIPOSOMES; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; PARTICLE SIZE; PEPTIDES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 85006699171     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S107107     Document Type: Article

References (55)

1. World Health Organization. Antimicrobial Resistance: Global Report on Surveillance. World Health Organization; 2014. Available from: http://www.who.int/drugresistance/documents/surveillancereport/en/. Accessed August 31, 2016.
2. Buick S, Joffe AM, Taylor G, Conly J. A consensus development conference model for establishing health policy for surveillance and screening of antimicrobial-resistant organisms. Clin Infect Dis. 2015;60(7): 1095-1101.
3. Lai C-C, Lee K, Xiao Y, et al. High burden of antimicrobial drug resistance in Asia. J Glob Antimicrob Resist. 2014;2(3):141-147.
4. Chang H-H, Cohen T, Grad YH, Hanage WP, O’Brien TF, Lipsitch M. Origin and proliferation of multiple-drug resistance in bacterial pathogens. Microbiol Mol Biol Rev. 2015;79(1):101-116.
5. Boucher HW, Talbot GH, Benjamin DK, et al. 10×20 Progress - development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(12):1685-1694.
6. Roemer T, Boone C. Systems-level antimicrobial drug and drug synergy discovery. Nat Chem Biol. 2013;9(4):222-231.
7. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. 2004;38(9):1279-1286.
8. Akova M, Daikos G, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect. 2012;18(5):439-448.
9. Giamarellou H, Galani L, Baziaka F, Karaiskos I. Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae. Antimicrob agents chemother. 2013;57(5):2388-2390.
10. Pieren M, Tigges M. Adjuvant strategies for potentiation of antibiotics to overcome antimicrobial resistance. Curr Opin Pharmacol. 2012; 12(5):551-555.
11. Ejim L, Farha MA, Falconer SB, et al. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat Chem Biol. 2011;7(6):348-350.
12. Farha MA, Brown ED. Discovery of antibiotic adjuvants. Nat Biotechnol. 2013;31(2):120-122.
13. Bush K, Courvalin P, Dantas G, et al. Tackling antibiotic resistance. Nat Rev Microbiol. 2011;9(12):894-896.
14. Imperi F, Massai F, Pillai CR, et al. New life for an old drug: the anthelmintic drug niclosamide inhibits Pseudomonas aeruginosa quorum sensing. Antimicrob Agents Chemother. 2013;57(2):996-1005.
15. Wu F, Meng G, He J, Wu Y, Wu F, Gu Z. Antibiotic-loaded chitosan hydrogel with superior dual functions: antibacterial efficacy and osteoblastic cell responses. ACS Appl Mater Interfaces. 2014;6(13): 10005-10013.
16. Zhao Y, Jiang X. Multiple strategies to activate gold nanoparticles as antibiotics. Nanoscale. 2013;5(18):8340-8350.
17. Zhou C, Wang M, Zou K, Chen J, Zhu Y, Du J. Antibacterial polypeptide-grafted chitosan-based nanocapsules as an “armed” carrier of anticancer and antiepileptic drugs. ACS Macro Letters. 2013;2(11):1021-1025.
18. Li C, Zhang X, Huang X, Wang X, Liao G, Chen Z. Preparation and characterization of flexible nanoliposomes loaded with daptomycin, a novel antibiotic, for topical skin therapy. Int J Nanomedicine. 2013;8: 1285-1292.
19. Hancock RE, Sahl H-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 2006;24(12): 1551-1557.
20. Hancock RE, Scott MG. The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci U S A. 2000;97(16):8856-8861.
21. Morris CJ, Beck K, Fox MA, Ulaeto D, Clark GC, Gumbleton M. Pegylation of antimicrobial peptides maintains the active peptide conformation, model membrane interactions, and antimicrobial activity while improving lung tissue biocompatibility following airway delivery. Antimicrob Agents Chemother. 2012;56(6):3298-3308.
22. Wu X, Wang Z, Li X, et al. In vitro and in vivo activities of antimicrobial peptides developed using an amino acid-based activity prediction method. Antimicrob Agents Chemother. 2014;58(9):5342-5349.
23. Scott MG, Dullaghan E, Mookherjee N, et al. An anti-infective peptide that selectively modulates the innate immune response. Nat Biotechnol. 2007;25(4):465-472.
24. Braff MH, Hawkins MA, Di Nardo A, et al. Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J Immunol. 2005; 174(7):4271-4278.
25. Karlsson AJ, Pomerantz WC, Weisblum B, Gellman SH, Palecek SP. Antifungal activity from 14-helical β-peptides. J Am Chem Soc. 2006; 128(39):12630-12631.
26. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415(6870):389-395.
27. Nagaoka I, Hirota S, Niyonsaba F, et al. Augmentation of the lipopoly-saccharide-neutralizing activities of human cathelicidin CAP18/LL-37-derived antimicrobial peptides by replacement with hydrophobic and cationic amino acid residues. Clin Diagn Lab Immunol. 2002;9(5): 972-982.
28. Vignoni M, de Alwis Weerasekera H, Simpson MJ, et al. LL37 peptide@silver nanoparticles: combining the best of the two worlds for skin infection control. Nanoscale. 2014;6(11):5725-5728.
29. Hancock RE, Lehrer R. Cationic peptides: a new source of antibiotics. Trends Biotechnol. 1998;16(2):82-88.
30. Travis S, Yap LM, Hawkey C, et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis. 2005;11(8):713-719.
31. Chen WL, Yuan ZQ, Liu Y, et al. Liposomes coated with N-trimethyl chitosan to improve the absorption of harmine in vivo and in vitro. Int J Nanomedicine. 2016;11:325.
32. Tateda K, Ishii Y, Matsumoto T, et al. Direct evidence for antip-seudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother. 1996;40(10):2271-2275.
33. Azhdarzadeh M, Lotfipour F, Zakeri-Milani P, Mohammadi G, Valizadeh H. Anti-bacterial performance of azithromycin nanoparticles as colloidal drug delivery system against different gram-negative and gram-positive bacteria. Adv Pharmal Bull. 2012;2(1):17.
34. Zakeri-Milani P, Ghanbarzadeh S, Lotfi poor F, Milani M, Valizadeh H. Pharmacokinetic study of two macrolide antibiotic oral suspensions using an optimized bioassay procedure. J Bioequiv Bioavailab. 2010;2: 111-115.
35. Sugie M, Asakura E, Zhao YL, et al. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother. 2004;48(3):809-814.
36. He Z, Yu Y, Zhang Y, et al. Gene delivery with active targeting to ovarian cancer cells mediated by folate receptor α. J Biomed Nanotechnol. 2013;9(5):833-844.
37. Gou M, Men K, Shi H, et al. Curcumin-loaded biodegradable polymeric micelles for colon cancer therapy in vitro and in vivo. Nanoscale. 2011;3(4):1558-1567.
38. Bruzzese F, Di Gennaro E, Avallone A, et al. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-α in head and neck cancer cells in vitro and in vivo. Clin Cancer Res. 2006;12(2):617-625.
39. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45-e45.
40. Gao H, He Q. The interaction of nanoparticles with plasma proteins and the consequent influence on nanoparticles behavior. Expert Opin Drug Deliv. 2014;11(3):409-420.
41. Liu Y, Mei L, Yu Q, et al. Multifunctional tandem peptide modified paclitaxel-loaded liposomes for the treatment of vasculogenic mimicry and cancer stem cells in malignant glioma. ACS Appl Mater Interfaces. 2015;7(30):16792-16801.
42. Zhang Q, Zhang X, Chen T, et al. A safe and efficient hepatocyte-selective carrier system based on myristoylated preS1/21-47 domain of hepatitis B virus. Nanoscale. 2015;7(20):9298-9310.
43. Tsuji M, Takema M, Miwa H, Shimada J, Kuwahara S. In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models. Antimicrob Agents Chemother. 2003; 47(8):2507-2512.
44. Wieczorek M, Jenssen H, Kindrachuk J, et al. Structural studies of a peptide with immune modulating and direct antimicrobial activity. Chem Biol. 2010;17(9):970-980.
45. Goldberg D, Winfield D. Diagnostic accuracy of serum enzyme assays for myocardial infarction in a general hospital population. Br Heart J. 1972;34(6):597.
46. Ozer JS, Chetty R, Kenna G, et al. Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury. Regul Toxicol Pharmacol. 2010;56(3):237-246.
47. Xin H, Sha X, Jiang X, Zhang W, Chen L, Fang X. Anti-glioblastoma efficacy and safety of paclitaxel-loading angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials. 2012;33(32): 8167-8176.
48. Li S-D, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 2008;5(4):496-504.
49. Kim BY, Rutka JT, Chan WC. Nanomedicine. N Engl J Med. 2010; 363(25):2434-2443.
50. Gong C, Yang T, Yang X, et al. Carrier-free nanoassemblies of a novel oxazolidinone compound FYL-67 display antimicrobial activity on methicillin-resistant Staphylococcus aureus. Nanoscale. 2013;5(1): 275-283.
51. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock RE. Impact of LL-37 on anti-infective immunity. J Leuko Biol. 2005;77(4): 451-459.
52. Cederlund A, Gudmundsson GH, Agerberth B. Antimicrobial peptides important in innate immunity. FEBS J. 2011;278(20):3942-3951.
53. Lin L, Nonejuie P, Munguia J, et al. Azithromycin synergizes with cationic antimicrobial peptides to exert bactericidal and therapeutic activity against highly multidrug-resistant Gram-negative bacterial pathogens. EBioMedicine. 2015;2(7):688-696.
54. Matijašić M, Kos VM, Nujić K, et al. Fluorescently labeled macrolides as a tool for monitoring cellular and tissue distribution of azithromycin. Pharmacol Res. 2012;66(4):332-342.
55. Sochacki KA, Barns KJ, Bucki R, Weisshaar JC. Real-time attack on single Escherichia coli cells by the human antimicrobial peptide LL-37. Proc Natl Acad Sci U S A. 2011;108(16):E77-E81.